Filing summary
Entity note: The supplied filing is Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp. It is an unaudited Form 10-Q for the quarter ended March 31, 2024. Unless stated otherwise, amounts below are in U.S. dollars.
Business context and reporting period
Ekso designs and sells powered and non-powered exoskeletons for medical rehabilitation and industrial use. Its reportable segments are EksoHealth and EksoWorks. The filing describes results for the three months ended March 31, 2024, compared with the same period in 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $3.756 million | $4.122 million; down 9% |
| Gross profit and margin | $1.951 million; 52% | $2.000 million; 49% |
| Operating expenses | $5.207 million | $6.448 million; down 19% |
| Operating loss | $(3.256) million | $(4.448) million |
| Net loss / diluted loss per share | $(3.429) million / $(0.20) | $(4.389) million / $(0.33) |
| Cash used in operating activities | $(3.466) million | $(4.214) million |
| Cash and restricted cash, at quarter-end | $8.799 million | $8.638 million at Dec. 31, 2023 |
| Working capital, at quarter-end | $13.2 million | $12.1 million at Dec. 31, 2023 |
| Notes payable, net, at quarter-end | $5.844 million | $6.082 million at Dec. 31, 2023 |
Cash flow also included $0.008 million used in investing activities and $3.657 million provided by financing activities. The financing inflow was principally from the January 2024 registered offering. Of the $8.799 million in cash and restricted cash, $2.0 million was subject to the lender’s liquidity covenant; the company reported approximately $6.8 million of effective unrestricted cash.
EksoHealth revenue was $3.559 million, versus $3.997 million; EksoWorks revenue was $0.197 million, versus $0.125 million. EksoHealth gross profit was $1.904 million (prior year $2.046 million); EksoWorks gross profit was $0.047 million (prior-year loss of $0.046 million).
Material changes versus the prior comparable period
- Revenue fell $0.366 million, mainly because of lower EksoNR sales in EksoHealth; higher Indego device sales partly offset the decline. EksoWorks growth reflected increased EVO sales.
- Gross margin improved to 52% from 49%, primarily due to lower EksoHealth device and service costs and supply-chain and service cost savings.
- Operating expenses declined $1.241 million, including lower general and administrative expense (less legal, headcount, and HMC acquisition/integration costs) and lower sales and marketing expense, primarily from reduced headcount.
- Net loss narrowed by $0.960 million. Results included a $0.342 million gain on warrant revaluation, a $0.109 million warrant-modification loss, and a $0.349 million unrealized foreign-exchange loss; the prior-year quarter included a $0.217 million foreign-exchange gain.
- Cash increased slightly after the company raised approximately $3.9 million net in its January registered direct offering and used $3.466 million in operating cash. Common shares outstanding were 18.096 million at March 31, up from 14.848 million at year-end.
Outlook, management commentary, risks, and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. It expects continued operating losses and negative operating cash flow and says additional financing is needed; its financing plans do not alleviate the substantial doubt. Management notes possible financing, expense reductions, delayed or abandoned development projects, and refocused sales efforts, but says there is no assurance financing will be available on acceptable terms.
- Cash obligations: Disclosed contractual obligations totaled $10.279 million, including $4.375 million of Parker promissory-note principal, $2.411 million of term-loan payments, $1.106 million of lease payments, and $2.387 million of purchase obligations. The Parker note is non-interest-bearing absent default and has scheduled quarterly principal installments; the PWB term loan matures in August 2026 and requires $2.0 million of qualifying cash to be maintained.
- Commercial opportunity and uncertainty: Management reported that CMS approved a final Medicare payment level of $91,031.93 for Ekso Indego Personal, effective April 1, 2024. Management expects the reimbursement decision may support demand, but sales depend on prescriptions, medical-necessity documentation, payer implementation and approvals, and reimbursement collection. No quantified revenue or earnings guidance is provided.
- Key risks: Financing availability and ongoing cash burn; product adoption and long, variable sales cycles; regulatory and clinical requirements; payer coverage and reimbursement; competition and pricing pressure; foreign-currency fluctuations; and product warranty, recall, and liability exposure. Two customers each represented at least 10% of receivables at quarter-end; one customer represented 11% of quarterly revenue.
- Other disclosures: The company reported no material changes to previously disclosed risk factors other than the added reimbursement risk discussion. Management said disclosure controls were effective and there were no material changes in internal control over financial reporting. Management did not expect ordinary-course legal matters to have a material adverse effect, while noting litigation outcomes are uncertain.
Most important facts for investors to verify
- Whether Ekso can secure sufficient financing, and how long its available unrestricted cash can fund operations at the current cash-burn rate.
- Whether the $2.0 million lender cash covenant remains satisfied and how the company will meet scheduled Parker note and other contractual payments.
- How CMS and regional DME MAC implementation affects actual Indego Personal coverage, claim approval, reimbursement timing, and unit sales following the April 1, 2024 effective date.
- Whether revenue trends improve, particularly EksoNR demand, and whether the improved gross margin can be sustained.
- The potential effects of equity financing, ATM sales, outstanding warrants, and other share-based awards on dilution and cash needs.